Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients
Erik Asmus, …, N. Suttorp, S. Hippenstiel, L. E Sander, F. Kurth, U. Rauch, U. Landmesser, A. Haghikia, R. Preissner, H. J Bogaard, M. Witzenrath, W. M Kuebler, R. Szulcek, S. Simmons – 2023
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators reduce agonist-induced platelet activation and function. CFTR modulators, such as ivacaftor, present a promising therapeutic strategy in thrombocytopathies, including severe COVID-19.
Title
Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients
Author
Erik Asmus, …, N. Suttorp, S. Hippenstiel, L. E Sander, F. Kurth, U. Rauch, U. Landmesser, A. Haghikia, R. Preissner, H. J Bogaard, M. Witzenrath, W. M Kuebler, R. Szulcek, S. Simmons
Date
2023
Identifier
10.1183/13993003.02009-2022
Source(s)
Citation
Eur Respir J, 2023, 61 (3), 2202009
Type
Text